Clinical trials: Recurrent Endometrial Carcinoma, open to volunteers
Endometrial Cancer
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Patients with advanced mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) endometrial cancer (EC) are currently treated as one entity, and immune checkpoint inhibitor (ICI) monotherapy is the treatment of…
- Trial name
- CAN-RESPOND (NCT05550558)
- Testing
- Anlotinib + Camrelizumab
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Uterine Cancer, Endometrial Cancer
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer.
- Trial name
- NCT06795009
- Testing
- Zanzalintinib, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with…
- Trial name
- NCT07198074
- Testing
- Bevacizumab, Biospecimen Collection, Carboplatin
- Where
- 309 sites in United States
- Volunteers
- 255 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Carcinoma, TP53 Mutation
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial…
- Conditions
- Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic
- Trial name
- NCT06413992
- Testing
- Fluzoparib, Camrelizumab, paclitaxel (albumin bound)
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Endometrial Neoplasms, Endometrial Cancer
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy.
- Trial name
- NCT07578649
- Testing
- PF-08634404, Pembrolizumab, Standard of Care Chemotherapy
- Where
- 54 sites in United States, Australia and 3 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Recurrent Gynecologic Cancer, Recurrent Uterine Cancer
Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total…
- Conditions
- Recurrent Gynecologic Cancer, Recurrent Uterine Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer
- Trial name
- Regynera-RT (NCT07667192)
- Testing
- Reirradiation, Total Ablative Strategy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous…
- Conditions
- Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03968406
- Testing
- Quality-of-Life Assessment, Radiation Therapy, Talazoparib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation…
- Trial name
- NCT05603910
- Testing
- Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Aaron Wolfson
Endometrial Cancer, Genetic Predisposition
Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors
Endometrial cancer (EC) is one of the most prevalent cancers in women worldwide with a significantly increasing incidence, especially in developed countries.
- Conditions
- Endometrial Cancer, Genetic Predisposition, Risk Behavior
- Trial name
- MPEC (NCT06680791)
- Where
- Czechia
- Volunteers
- 280 people
- Sponsor
- Lukas Vanek
Neoplasms, Endometrial
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
- Trial name
- NCT06897527
- Testing
- Dostarlimab
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Endometrial Carcinoma, Serous Carcinoma
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation…
- Trial name
- NCT04716686
- Testing
- Niraparib
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Shandong University
Endometrial Cancer
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair…
- Trial name
- NCT07270666
- Testing
- ctDNA Testing, Blood draw, Surveys
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Neoplasms
Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial
Minimally invasive surgery is the recommended approach in endometrial cancer (EC) patients based on the results of two randomized controlled trials, given its advantages without compromised oncologic outcomes.
- Trial name
- MANEC (NCT05687084)
- Testing
- Uterine manipulator use
- Where
- 3 sites in Italy
- Volunteers
- 1,030 people
- Sponsor
- Universita di Verona
Endometrial Cancer
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy.
- Trial name
- NCT05797831
- Testing
- Navtemadlin
- Where
- 83 sites in United States, Austria and 15 more
- Volunteers
- 268 people
- Sponsor
- Kartos Therapeutics, Inc.
Endometrial Cancer
3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer
To verify the safety of omission of lymph node dissection in ultra-low-risk endometrial cancer (KGOG criteria), we examine the survival of women with ultra-low-risk endometrial cancer who do not undergo lymph node dissection
- Trial name
- TREE PRO (NCT04227249)
- Testing
- no lymph node dissection
- Volunteers
- 153 people
- Sponsor
- Seoul National University Hospital
Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6.
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07807345
- Testing
- STRO-006, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 285 people
- Sponsor
- Sutro Biopharma, Inc.
Endometrial Cancer
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.
- Trial name
- NCT07209449
- Testing
- Abemaciclib, Elacestrant
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APOLLO (NCT07909031)
- Testing
- CR-002
- Where
- 3 sites in United States
- Volunteers
- 219 people
- Sponsor
- Crescent Biopharma, Inc.
Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or…
- Trial name
- RAINFOL-03 (NCT07166094)
- Testing
- Rina-S, IC
- Where
- 178 sites in United States, Australia and 17 more
- Volunteers
- 660 people
- Sponsor
- Genmab